Company profile for ExpreS2ion Biotechnologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ExpreS2ion has since its announcement on February 6th, 2020 of initiating a vaccine development programme against COVID-19 worked diligently to progress on its project, including setting up consortia of viral research and clinical vaccine experts, which together with our ExpreS2 protein production platform and our joint venture AdaptVac’s cVLP technology as core enabling technologies increase the likelihood of a unique vacci...
ExpreS2ion has since its announcement on February 6th, 2020 of initiating a vaccine development programme against COVID-19 worked diligently to progress on its project, including setting up consortia of viral research and clinical vaccine experts, which together with our ExpreS2 protein production platform and our joint venture AdaptVac’s cVLP technology as core enabling technologies increase the likelihood of a unique vaccine with stronger and long lasting immune response. We are very proud of being part of this EU’s Horizon 2020 award, that supports our ambitious timeline of initiating clinical investigations within 12 months.”

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Denmark
Address
Address
SCION-DTU Science Park Agern Allé 1 DK-2970 Horsholm Denmark
Telephone
Telephone
+45 2222 1019
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Evaxion and ExpreS²ion partner to develop new CMV vaccine
Evaxion and ExpreS²ion partner to develop new CMV vaccine

06 Dec 2022

// PHARMACEUTICAL-TECHNOLOGY

https://www.pharmaceutical-technology.com/news/evaxion-expres%c2%b2ion-cmv-vaccine/

PHARMACEUTICAL-TECHNOLOGY
06 Dec 2022

https://news.cision.com/expres2ion-biotechnologies/r/first-subject-vaccinated-in-covid-19-phase-iii-clinical-trial-for-abncov2-as-a-booster-vaccine,c3623296

CISION
02 Sep 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty